Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,911.15
    +3,801.49 (+8.07%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

AstraZeneca raises bet on Japan by buying out Sumitomo

Reuters - UK Focus

LONDON, March 26 (Reuters) - AstraZeneca (NYSE: AZN - news) has raised its bet on Japan's drug market by buying out the remaining stake held by Sumitomo Chemical in its Japanese unit AstraZeneca K.K.

The British group said on Wednesday the purchase of the shares cost approximately 10 billion yen ($102 million) and reinforced its focus on Japan as a key growth platform.

Japan, the world's second-largest pharmaceuticals market after the United States, is an increasingly important country for Western drugmakers.

In the past, it has been a tough market for foreign drug firms to crack, but recent steps to speed up the approval process have opened the door to a raft of commercially important drugs. (Reporting by Ben Hirschler; Editing by Mark Potter)